The IRF2 Knockout HT29 Polyclonal Cells product provides a polyclonal population of HT29 colorectal adenocarcinoma cells carrying CRISPR/Cas9-mediated gene disruption at the IRF2 locus. This approach generates a heterogeneous pool of knockout variants, collectively abolishing IRF2 protein function while maintaining genetic diversity. The polyclonal format avoids clonal artifacts and enables robust population-level analyses, making it appropriate for experiments requiring representation of cellular heterogeneity. As a loss-of-function model, this product enables precise dissection of IRF2-dependent regulatory mechanisms in a human epithelial setting.
The parental HT29 cell line is a well-characterized colorectal adenocarcinoma model featuring an activating APC mutation and wild-type TP53. These cells can undergo enterocytic differentiation under metabolic stress or specific culture conditions, recapitulating features of the intestinal epithelium. HT29 is widely employed in studies of epithelial barrier function, colorectal cancer biology, and drug response. Its p53 proficiency and differentiation capacity provide a relevant genomic context for investigating how IRF2 knockout impacts cell cycle regulation, apoptosis, and immune-related gene expression.
IRF2 is an interferon regulatory transcription factor that acts primarily as a transcriptional repressor, antagonizing IRF1-mediated gene activation. It is regulated downstream of IFN-?? and IFN-??/?? through JAK-STAT signaling, involving kinases JAK1 and TYK2, and transcription factors STAT1 and STAT2. IRF2 interacts with co-repressors such as Sin3A and binding partners IRF2BP1, IRF2BP2, and NF-??B to suppress target genes. In the absence of IRF2, repression is relieved on key targets including IRF1, CDKN1A (p21), MDM2, CASP1, and Bcl-2 family members, leading to enhanced cell cycle inhibition and pro-apoptotic signaling.
In HT29 cells, the constitutively active Wnt pathway due to APC mutation drives proliferation, while intact p53 permits checkpoint and apoptotic responses. IRF2 knockout deepens the interferon-induced anti-proliferative state by upregulating p21 and pro-apoptotic factors, potentially augmenting p53-mediated outcomes. This model is well-suited for studying interferon-dependent immune evasion in colorectal cancer, exploring crosstalk between Wnt and interferon pathways, and assessing epithelial inflammatory responses relevant to inflammatory bowel disease. It can also be used to evaluate how IRF2 loss influences chemotherapeutic sensitivity.
Key applications include investigating IRF2??s role in interferon-?? signaling and tumor immune escape, screening chemotherapeutics and immunomodulatory compounds, and examining inflammatory gene regulation in epithelial cells. Representative assays comprise Western blotting and RT-qPCR for IRF2 and target gene expression, RNA-seq transcriptomics, flow cytometry for apoptosis and cell cycle phases, immunofluorescence for protein localization, co-immunoprecipitation of IRF2 complexes, and phospho-STAT1 analysis. The polyclonal population is also amenable to pooled functional genomics screens. For further details, please contact Ascent Research.
